The following FOI is answered in relation to the time period 01/04/24 - 30/06/24.
Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?
Yes
Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:
· Dostarlimab (Jemperli) - <5
· Dostarlimab (Jemperli) AND Chemotherapy - <5
· Hormone therapy (Progesterone or Letrozole) - NIL
· Pembrolizumab (Keytruda) monotherapy - NIL
· Lenvatinib + Pembrolizumab (Lenvima +Keytruda) - <5
· Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) - 17
· Any other SACT - <5
Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?
6
Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:
· Dostarlimab (Jemperli) AND Chemotherapy - <5
· Hormone therapy (Progesterone or Letrozole) - NIL
· Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) - 11
· Any other SACT - NIL
Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.
The Trust do not currently have any clinical trials in this area.
